In the News

Le Dauphine Libere
National Institute for Health Research
Lokalzeit aus Bonn (March 26, 2015)
9 News (March 9, 2015)
WDRB (March 1, 2015)
The Courier-Journal (Feb 25, 2015)
Clinica (Feb 2, 2015)
U of L Today (Jan 28, 2015)

Press Releases

REDWOOD CITY, California, December 10, 2018 – Pulmonx, a leader in interventional pulmonary device technology announced today that the National Institute for Health and Care Excellence (NICE) in the UK has expanded its guidance on the diagnosis and management of COPD to include which patients should...

Read more

REDWOOD CITY, Calif. – June 29, 2018 – Pulmonx® Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the first minimally-invasive device approved in the United States for...

Read more

SAN DIEGO and REDWOOD CITY, Calif. – May 22, 2018 – Pulmonx® Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD)....

Read more

Zephyr EBVs are the Only Minimally-Invasive, Removable Devices for Emphysema with Validated Diagnostic Tool to Select Patients Likely to Benefit from Treatment

Read more
CAUTION: The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use.
US / new visitor